The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11091-11095

  Yang, Xiangshan ^a   Li, Daotang ^a   Cheng, Shaomei ^a   Fan, Kaixi ^a   Sheng, Lijun ^a   Zhang, Jing ^a   Feng, Bin ^a   Xu, Zhongfa ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

BMP2; Glioma; Immunohistochemistry; Prognosis

Indexed keywords

BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BRAIN TUMOR; CANCER GRADING; CHILD; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GLIOMA; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 2; BRAIN NEOPLASMS; CHILD; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84927800251     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2424-9     Document Type: Article

References (23)

1. Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist. 2014;19:751–9.
2. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50.
3. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000;88:2887.
4. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.
5. Hou CH, Hsiao YC, Fong YC. Bone morphogenetic protein 2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase 13. Bone. 2009;2:233–42.
6. ten Dijke P, Korchynskyi O, Valdimarsdottir G. Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol. 2003;211:105–13.
7. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 2006;25:685–92.
8. Arnold SF, Tims E, Mcgrath BE. Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. Cytokine. 1999;11:1031–7.
9. Yang ZJ, Liu FX, Yang YS, Yang X, Zhu GX. Expression of bone-morphogenetic protein 2 and tumor necrosis factor α correlates with bone metastases in bladder urothelial carcinoma. Ann Diagn Pathol. 2013;17:51–3.
10. Davies SR, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance. J Exp Ther Oncol. 2008;7:327–38.
11. Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, Kim JS, et al. Metastatic function of BMP2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression. Exp Cell Res. 2011;317:1746–62.
12. Langenfeld EM, Bojnowski J, Perone J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg. 2005;80:1028–32.
13. Ma Y, Ma L, Guo Q, Zhang S. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J Exp Clin Cancer Res. 2010;29:85.
14. Goumans MJ, Mummery C. Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int J Dev Biol. 2000;44:253–65.
15. Yang ZJ, Liu FX, Yang YS, Yang X, Zhu GX. Expression of bone-morphogenetic protein 2 and tumor necrosis factor α correlates with bone metastases in bladder urothelial carcinoma. Ann Diagn Pathol. 2013;17:51–3.
16. Zhang Y, Chen X, Qiao M, Zhang BQ, Wang N, Zhang Z, et al. Bone morphogenetic protein 2 inhibits the proliferation and growth of human colorectal cancer cells. Oncol Rep. 2014. doi:10.3892/or.2014.3308.
17. Fei ZH, Yao CY, Yang XL, Huang XE, Ma SL. Serum BMP2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2013;14:5293–9.
18. Clement JH, Raida M, Sänger J, Bicknell R, Liu J, Naumann A, et al. Bone morphogenetic protein 2 (BMP2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol. 2005;27:401–7.
19. Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res. 2010;316:24–37.
20. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 2003;24:1445–54.
21. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004;2:141–9.
22. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone. 2006;38:154–66.
23. Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, et al. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis. 2012;3:e412.